Financials Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-05-23 am EDT 5-day change 1st Jan Change
21.45 HKD -0.23% Intraday chart for Sinopharm Group Co. Ltd. -3.81% +4.89%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 75,452 49,504 43,125 54,681 58,004 62,228 - -
Enterprise Value (EV) 1 91,399 63,204 63,166 64,207 58,004 73,721 71,585 73,485
P/E ratio 12.1 x 6.87 x 5.55 x 6.42 x 6.41 x 6.46 x 5.87 x 5.37 x
Yield 2.36% 4.35% 5.43% 4.68% - 4.68% 5.15% 5.55%
Capitalization / Revenue 0.18 x 0.11 x 0.08 x 0.1 x 0.1 x 0.1 x 0.09 x 0.08 x
EV / Revenue 0.21 x 0.14 x 0.12 x 0.12 x 0.1 x 0.11 x 0.1 x 0.1 x
EV / EBITDA 5.09 x 3.21 x 2.67 x 2.59 x 2.35 x 2.81 x 2.5 x 2.36 x
EV / FCF 6.57 x -13.8 x 9.72 x 3.47 x - 15.5 x 7.57 x 7.86 x
FCF Yield 15.2% -7.24% 10.3% 28.8% - 6.47% 13.2% 12.7%
Price to Book 1.59 x 0.88 x 0.7 x 0.8 x - 0.75 x 0.67 x 0.61 x
Nbr of stocks (in thousands) 2,967,629 3,118,654 3,120,656 3,120,656 3,120,656 3,120,656 - -
Reference price 2 25.42 15.87 13.82 17.52 18.59 19.94 19.94 19.94
Announcement Date 3/30/20 3/21/21 3/20/22 3/26/23 3/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 425,273 456,415 521,051 552,148 596,570 648,680 706,560 770,918
EBITDA 1 17,950 19,667 23,634 24,769 24,639 26,207 28,646 31,141
EBIT 1 16,137 17,760 19,712 20,604 20,209 23,077 25,221 27,538
Operating Margin 3.79% 3.89% 3.78% 3.73% 3.39% 3.56% 3.57% 3.57%
Earnings before Tax (EBT) 1 13,760 15,598 17,003 18,564 19,512 20,858 22,958 25,119
Net income 1 6,253 7,187 7,759 8,526 9,054 9,628 10,594 11,603
Net margin 1.47% 1.57% 1.49% 1.54% 1.52% 1.48% 1.5% 1.51%
EPS 2 2.100 2.310 2.490 2.730 2.900 3.089 3.396 3.716
Free Cash Flow 1 13,909 -4,574 6,501 18,481 - 4,771 9,453 9,355
FCF margin 3.27% -1% 1.25% 3.35% - 0.74% 1.34% 1.21%
FCF Conversion (EBITDA) 77.49% - 27.51% 74.61% - 18.21% 33% 30.04%
FCF Conversion (Net income) 222.46% - 83.79% 216.77% - 49.56% 89.22% 80.62%
Dividend per Share 2 0.6000 0.6900 0.7500 0.8200 - 0.9338 1.027 1.108
Announcement Date 3/30/20 3/21/21 3/20/22 3/26/23 3/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 S1
Net sales 1 223,608 203,765 252,650 249,120 271,931 261,472 290,676 18,687 155,433 300,950 144,969 150,650 295,619 311,580
EBITDA - - - - - - - - - - - - - -
EBIT 1 - - - 8,772 10,940 9,057 11,547 - 5,895 10,869 5,937 4,691 10,628 10,518
Operating Margin - - - 3.52% 4.02% 3.46% 3.97% - 3.79% 3.61% 4.1% 3.11% 3.6% 3.38%
Earnings before Tax (EBT) 1 - - - - - - - - 5,228 8,866 4,161 6,485 - -
Net income - - - - - - - 362.2 2,514 4,104 1,752 - - -
Net margin - - - - - - - 1.94% 1.62% 1.36% 1.21% - - -
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 3/30/20 8/23/20 3/21/21 8/22/21 3/20/22 8/29/22 3/26/23 4/17/23 8/27/23 8/27/23 10/30/23 3/24/24 3/24/24 -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,947 13,699 20,041 9,526 - 11,492 9,357 11,256
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.8884 x 0.6966 x 0.848 x 0.3846 x - 0.4385 x 0.3266 x 0.3615 x
Free Cash Flow 1 13,909 -4,574 6,501 18,481 - 4,771 9,453 9,355
ROE (net income / shareholders' equity) 13.9% 13.9% 13.1% 13.1% - 11.9% 11.9% 11.6%
ROA (Net income/ Total Assets) 2.47% 2.47% 2.4% 2.44% - 2.38% 2.42% 2.41%
Assets 1 252,832 290,559 323,331 350,101 - 405,034 438,563 481,802
Book Value Per Share 2 16.00 18.10 19.80 21.80 - 26.70 29.70 32.90
Cash Flow per Share 2 6.320 3.590 2.980 6.720 - 6.040 3.430 6.080
Capex 1 4,868 4,585 2,807 2,482 - 3,177 3,022 3,156
Capex / Sales 1.14% 1% 0.54% 0.45% - 0.49% 0.43% 0.41%
Announcement Date 3/30/20 3/21/21 3/20/22 3/26/23 3/24/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
19.94 CNY
Average target price
24.61 CNY
Spread / Average Target
+23.42%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 1099 Stock
  4. Financials Sinopharm Group Co. Ltd.